Lidocaine 5% Medicated Plaster in Chronic Neuropathic Postoperative Pain

Grünenthal

Status and phase

Terminated

Phase 2

Conditions

Postoperative Pain

Neuropathic Pain

Chronic Pain

Pain

Treatments

Drug: Lidocaine 5% medicated plaster

Drug: Placebo topical plaster

Study type

Interventional

Funder types

Industry

Identifiers

NCT01155986

761541

2009-016337-10 (EudraCT Number)

Details and patient eligibility

About

The purpose of this trial is to investigate the efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain in comparison to placebo plaster.

Full description

Some patients who undergo different types of surgery develop distressing and long-lasting pain. This pain is often characterized by signs such as: allodynia (a pain due to a stimulus which does not normally provoke pain), dysesthesia (unpleasant, abnormal sense of touch). Patients describe symptoms of burning or electrical type sensation. In some cases this type of chronic pain can still be present after 3 months or more following surgery.This clinical trial will assess the efficacy and safety profile of lidocaine 5% medicated plaster in comparison to placebo plaster in patients.

This trial is a randomized, double-blind (neither investigator nor patient will know which treatment was received), placebo-controlled, parallel-group, multicenter trial to evaluate topical analgesic treatment of chronic neuropathic pain after surgery. The trial will include a screening phase and a treatment phase, during which subjects will be treated with either 5% lidocaine medicated plaster, or a placebo plaster pain intensity will be assessed on a daily basis. Subsequently there will be a follow-up phase. Pain intensity numeric rating scale (PI) will be collected via the numeric rating scale and averaged. Safety evaluations include monitoring of adverse events, physical examinations, and clinical laboratory tests.

Enrollment

74 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female subjects with >= 18 years of age
Intact skin in the area of topical treatment
Patients suffering from moderate to severe ( 5 or more points on an 11 point Numerical Rating Scale where 10 is the worst possible pain, and 0 indicates no pain) chronic daily postoperative neuropathic pain for the past 6 to 24 months.
Patients should have symptoms for example allodynia (a pain due to a stimulus which does not normally provoke pain); and or dysesthesia (unpleasant, abnormal sense of touch).

Exclusion criteria

Contraindications to lidocaine 5% medicated plaster, or paracetamol
Evidence or history of alcohol, medication or drug abuse and/or dependency in the past 3 years.
Evidence or history (during the past 3 years) of epilepsy, neurotic personality, psychiatric illness, or suicide risk.
Pregnant or breastfeeding women
Women of childbearing potential who are sexually active without satisfactory contraception for at least 28 days prior to enrollment, during the trial, and until 28 days after the follow-up visit.
Severe renal, hepatic or heart disorder.
Surgery in the past 3 months before screening.
Anticipated need for surgery during the trial, requiring at least regional or general anesthesia.
Pending litigation due to chronic pain or disability.
Participation in another trial of investigational medicinal products or devices parallel to or less than 1 month before entry into the trial, or previous participation in this trial.
Presence of other severe pain that could confound the assessment or self- evaluation of the localized postoperative neuropathic pain.
For patients with chronic postoperative neuropathic pain related to a surgery due to tumors: suspected residual tumor or metastases, chemotherapy or radiotherapy for treatment of tumor(s).
Total anesthesia in the area of localized chronic pain